<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03965845</url>
  </required_header>
  <id_info>
    <org_study_id>CX-839-012</org_study_id>
    <nct_id>NCT03965845</nct_id>
  </id_info>
  <brief_title>A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors</brief_title>
  <official_title>A Phase 1b/2, Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination With CDK4/6 Inhibitor Palbociclib in Patients With Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Calithera Biosciences, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Calithera Biosciences, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b/2 study to determine the recommended phase 2 dose (RP2D), safety and&#xD;
      tolerability, pharmacokinetics (PK) and clinical activity of the glutaminase inhibitor&#xD;
      telaglenestat (CB-839) with the CDK4/6 Inhibitor, palbociclib in participants with&#xD;
      advanced/metastatic solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 25, 2019</start_date>
  <completion_date type="Actual">September 24, 2021</completion_date>
  <primary_completion_date type="Actual">September 24, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of telaglenestat (CB-839) in combination with palbociclib: (CR) number of participants with treatment related adverse events</measure>
    <time_frame>Start of treatment to 28 days post treatment</time_frame>
    <description>Number of participants with treatment related adverse events as assessed by CTCAE v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose and/or Recommended Phase 2 Dose:</measure>
    <time_frame>Measured from Part 1 patients only within their first 28 day cycle</time_frame>
    <description>Incidence and nature of dose-limiting toxicities</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration of telaglenastat and palbociclib:</measure>
    <time_frame>PKs are drawn on two different days (Day 8 and Day 15) during Cycle 1</time_frame>
    <description>Non-compartmental method of analysis will be used to analyze the plasma concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity of telaglenestat and palbociclib:</measure>
    <time_frame>Approximately every 8 weeks until disease progression, for approximately 18 months</time_frame>
    <description>Change in tumor size from baseline</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Solid Tumors</condition>
  <condition>NSCLC</condition>
  <condition>CRC</condition>
  <condition>KRAS Gene Mutation</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Telaglenastat 600 mg and Palbociclib 75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Telaglenastat 800 mg and Palbociclib 75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Telaglenastat 800 mg and Palbociclib 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Telaglenastat 800 mg and Palbociclib 125 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The recommended phase 2 dose (RP2D) determined from Part 1 will be the treatment for all cohorts in expansion Part 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telaglenestat (CB-839)</intervention_name>
    <description>Teleglenastat is an oral tablet administered twice daily with food at the assigned dose level. Dose is taken with palbociclib each day in 28-day cycles.</description>
    <arm_group_label>Cohort 1: Telaglenastat 600 mg and Palbociclib 75 mg</arm_group_label>
    <arm_group_label>Cohort 2: Telaglenastat 800 mg and Palbociclib 75 mg</arm_group_label>
    <arm_group_label>Cohort 3: Telaglenastat 800 mg and Palbociclib 100 mg</arm_group_label>
    <arm_group_label>Cohort 3: Telaglenastat 800 mg and Palbociclib 125 mg</arm_group_label>
    <arm_group_label>Part 2: Expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib Oral Capsule or Tablet [Ibrance]</intervention_name>
    <description>Palbociclib (Ibrance) is an oral capsule or tablet administered once daily with food on Days 1-21 of every 28-day cycle in combination with telaglenestat. Days 22-28 of every cycle, palbociclib is not taken.</description>
    <arm_group_label>Cohort 1: Telaglenastat 600 mg and Palbociclib 75 mg</arm_group_label>
    <arm_group_label>Cohort 2: Telaglenastat 800 mg and Palbociclib 75 mg</arm_group_label>
    <arm_group_label>Cohort 3: Telaglenastat 800 mg and Palbociclib 100 mg</arm_group_label>
    <arm_group_label>Cohort 3: Telaglenastat 800 mg and Palbociclib 125 mg</arm_group_label>
    <arm_group_label>Part 2: Expansion</arm_group_label>
    <other_name>Ibrance</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Part 1: Have documented incurable/locally advanced or metastatic solid tumors that&#xD;
             have either relapsed or are refractory or intolerant to the standard therapies of&#xD;
             proven clinical benefit.&#xD;
&#xD;
          -  Part 2: Availability of archival tumor tissue block or slides (Fresh tumor biopsy will&#xD;
             be required if archival tissue is not available)&#xD;
&#xD;
          -  Part 2, Cohort 1: Incurable/locally advanced or metastatic KRAS-mutant CRC previously&#xD;
             treated with systemic therapy (examples include: oxaliplatin-, irinotecan-and 5&#xD;
             FU-based chemotherapy (unless contraindicated) with or without bevacizumab)&#xD;
&#xD;
          -  Part 2, Cohort 2: Incurable/locally advanced or metastatic KRAS-mutant NSCLC&#xD;
             previously treated with systemic chemotherapy including platinum-based and&#xD;
             anti-PD-1/PDL-1 therapy (unless contraindicated)&#xD;
&#xD;
          -  Part 2, Cohort 3: Advance KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)&#xD;
             harboring a mutation or loss in CDKN2A (PDAC) and received treatment with one or more&#xD;
             lines of systemic chemotherapy with FOLFIRINOX and/or gemcitabine/abraxane in the&#xD;
             neoadjuvant, adjuvant, or metastatic disease setting or unable to receive standard of&#xD;
             care chemotherapy&#xD;
&#xD;
        Cohort 4 may be opened only if Cohort 3 achieves predefined criteria for efficacy&#xD;
&#xD;
        -Part 2 Cohort 4: Advanced KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC). Â·&#xD;
        Histological or cytological diagnosis of advanced or metastatic KRAS-mutant with CDKN2A&#xD;
        wild type (PDAC) and received treatment with one or more lines of systemic chemotherapy&#xD;
        with FOLFIRINOX and/or gemcitabine/abraxane in the neoadjuvant, adjuvant, or metastatic&#xD;
        disease setting or unable to receive standard of care chemotherapy.&#xD;
&#xD;
        For both Part 1 and 2:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1&#xD;
&#xD;
          -  Ability to provide written consent in accordance with federal, local and institutional&#xD;
             guidelines&#xD;
&#xD;
          -  PER RECIST v1.1 evaluable disease (for part 1) or measurable disease (for Part 2)&#xD;
&#xD;
          -  Recovery to baseline or to Grade 1 CTCAE v5.0 of toxicities that were related to prior&#xD;
             therapies&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with CB-839 or palbociclib&#xD;
&#xD;
          -  Unable to receive oral medication&#xD;
&#xD;
          -  Infection requiring more than 5 days of parenteral antibiotics, antivirals, or&#xD;
             antifungals within two weeks prior to C1D1&#xD;
&#xD;
          -  Unable to discontinue proton pump inhibitor use before study treatment&#xD;
&#xD;
          -  Refractory nausea and vomiting, uncontrolled diarrhea, malabsorption, significant&#xD;
             small bowel resection or gastric bypass surgery, use of feeding tubes or other&#xD;
             situation that may preclude adequate absorption&#xD;
&#xD;
          -  Active and/or untreated central nervous system metastasis. Patients with treated brain&#xD;
             metastasis must have (1) documented radiographic stability of at least 4 weeks in&#xD;
             duration demonstrating on baseline central nervous system imaging prior to study&#xD;
             treatment and (2) be symptomatically stable and off steroids for at least 2 weeks&#xD;
             before administration of any study treatment.&#xD;
&#xD;
          -  Major surgery within 28 days prior to first dose of study drug&#xD;
&#xD;
          -  Receipt of any anticancer therapy within the following windows:&#xD;
&#xD;
               1. small molecule TKI therapy (including investigational) within 2 weeks or 5&#xD;
                  half-lives prior to expected Cycle 1 Day 1 dose&#xD;
&#xD;
               2. any type of anti-cancer antibody or cytotoxic chemo within 4 weeks prior to Cycle&#xD;
                  1 Day 1 Dose&#xD;
&#xD;
               3. radiation therapy for bone metastasis within 2 weeks prior or any other external&#xD;
                  radiation therapy within 4 weeks prior to C1D1&#xD;
&#xD;
               4. patients with clinically relevant ongoing complications from prior radiation&#xD;
                  therapy are not eligible&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emil Kuriakose, MD</last_name>
    <role>Study Director</role>
    <affiliation>Calithera Biosciences, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA Hematology/Oncology</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory, Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regions Cancer care Center</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute- Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutic, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Clinical Science Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 24, 2019</study_first_submitted>
  <study_first_submitted_qc>May 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 29, 2019</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tumor Metabolism</keyword>
  <keyword>Glutaminase Inhibitor</keyword>
  <keyword>CB-839</keyword>
  <keyword>Palbociclib</keyword>
  <keyword>PALBO</keyword>
  <keyword>Telaglenestat</keyword>
  <keyword>CDK4/6</keyword>
  <keyword>CDK4</keyword>
  <keyword>CDK6</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Palbociclib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

